Literature DB >> 8353902

Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?

A M Lincoff1, E J Topol.   

Abstract

Thrombolytic therapy significantly improves the natural history of acute myocardial infarction, but recent data suggest that current reperfusion strategies have yet to realize the maximum potential for reduction of mortality and salvage of ventricular function. Coronary patency rates as high as 85% assessed by angiography 90 minutes after initiation of treatment greatly overestimate the efficacy of thrombolytic regimens, as this conventional angiographic "snapshot" view does not satisfactorily reflect the dynamic processes of coronary artery recanalization and reocclusion or the adequacy of myocardial perfusion. In fact, only the unusual patient appears to achieve optimal reperfusion for acute myocardial infarction, with a substantial deterioration of benefit in many patients due to insufficiently early or rapid recanalization, incomplete patency with TIMI grade 2 flow or critical residual coronary stenoses, absence of myocardial tissue reflow despite epicardial artery patency, intermittent coronary patency, subsequent reocclusion, or reperfusion injury. Recently developed techniques to critically assess the quality of reperfusion, coupled with the introduction of novel pharmacological agents and an improved understanding of the roles and mechanisms of existing thrombolytic and adjunctive drugs, have provided the opportunity to overcome many of the present limitations of reperfusion therapy. Emerging strategies to achieve optimal reperfusion are directed at enhancement of the velocity and quality of thrombolysis, amelioration of the adverse effects of reperfusion, and use of alternative pathways to myocardial salvage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353902     DOI: 10.1161/01.cir.88.3.1361

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  56 in total

1.  Current Clinical Experience with Staphylokinase in Arterial Thrombosis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Thrombolytic Therapy: The Treatment of Choice in Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Lethal Reperfusion Injury: Does Anyone Still Care?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

4.  Does "Lethal Reperfusion Injury" Exist?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

Review 5.  Platelet glycoprotein IIb/IIIa inhibitors combined with fibrinolytic agents to treat acute myocardial infarction.

Authors:  P L L'Allier; A M Lincoff
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 6.  Coronary Disease: Acute myocardial infarction: failed thrombolysis.

Authors:  M A de Belder
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 7.  Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.

Authors:  U Martin; B Kaufmann; G Neugebauer
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

Review 8.  Acute myocardial infarction: reperfusion treatment.

Authors:  Flavio Ribichini; William Wijns
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

Review 9.  ST-segment monitoring in patients with acute coronary syndromes.

Authors:  Per Johanson; Galen S Wagner; Mikael Dellborg; Mitchell W Krucoff
Journal:  Curr Cardiol Rep       Date:  2003-07       Impact factor: 2.931

10.  Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Authors:  Ulf Bertram; Martin Moser; Karlheinz Peter; Helmut F Kuecherer; Raffi Bekeredjian; Andreas Straub; Thomas K Nordt; Christoph Bode; Johannes Ruef
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.